Eledon Pharmaceuticals Stock Performance
| ELDN Stock | USD 2.09 0.04 1.88% |
On a scale of 0 to 100, Eledon Pharmaceuticals holds a performance score of 6. The firm shows a Beta (market volatility) of 2.56, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Eledon Pharmaceuticals will likely underperform. Please check Eledon Pharmaceuticals' potential upside, and the relationship between the jensen alpha and daily balance of power , to make a quick decision on whether Eledon Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Eledon Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain fundamental indicators, Eledon Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.88) | Five Day Return 5.56 | Year To Date Return 29.01 | Ten Year Return (99.78) | All Time Return (99.95) |
Last Split Factor 1:18 | Dividend Date 2020-10-05 | Last Split Date 2020-10-05 |
1 | Acquisition by Robinson James A. Jr. of 30870 shares of Eledon Pharmaceuticals at 4.04 subject to Rule 16b-3 | 11/26/2025 |
2 | Eledon Pharmaceuticals, Inc. Receives Consensus Rating of Hold from Brokerages | 01/16/2026 |
3 | Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 | 02/05/2026 |
| Begin Period Cash Flow | 4.6 M | |
| Total Cashflows From Investing Activities | -70.3 M |
Eledon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 176.00 in Eledon Pharmaceuticals on November 13, 2025 and sell it today you would earn a total of 33.00 from holding Eledon Pharmaceuticals or generate 18.75% return on investment over 90 days. Eledon Pharmaceuticals is currently generating 0.3905% in daily expected returns and assumes 4.6085% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Eledon, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eledon Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Eledon Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.09 | 90 days | 2.09 | about 32.75 |
Based on a normal probability distribution, the odds of Eledon Pharmaceuticals to move above the current price in 90 days from now is about 32.75 (This Eledon Pharmaceuticals probability density function shows the probability of Eledon Stock to fall within a particular range of prices over 90 days) .
Eledon Pharmaceuticals Price Density |
| Price |
Predictive Modules for Eledon Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Eledon Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Eledon Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Eledon Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Eledon Pharmaceuticals is not an exception. The market had few large corrections towards the Eledon Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Eledon Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Eledon Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.81 | |
β | Beta against Dow Jones | 2.56 | |
σ | Overall volatility | 0.47 | |
Ir | Information ratio | -0.09 |
Eledon Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Eledon Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Eledon Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Eledon Pharmaceuticals had very high historical volatility over the last 90 days | |
| Eledon Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (36.18 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eledon Pharmaceuticals currently holds about 70.46 M in cash with (47.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Robinson James A. Jr. of 30870 shares of Eledon Pharmaceuticals at 4.04 subject to Rule 16b-3 |
Eledon Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Eledon Stock often depends not only on the future outlook of the current and potential Eledon Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Eledon Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 48.5 M | |
| Cash And Short Term Investments | 140.2 M |
Eledon Pharmaceuticals Fundamentals Growth
Eledon Stock prices reflect investors' perceptions of the future prospects and financial health of Eledon Pharmaceuticals, and Eledon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eledon Stock performance.
| Return On Equity | -0.95 | ||||
| Return On Asset | -0.44 | ||||
| Current Valuation | 77.33 M | ||||
| Shares Outstanding | 79.63 M | ||||
| Price To Book | 4.81 X | ||||
| EBITDA | (35.39 M) | ||||
| Net Income | (36.18 M) | ||||
| Cash And Equivalents | 70.46 M | ||||
| Cash Per Share | 5.12 X | ||||
| Total Debt | 954 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 22.22 X | ||||
| Book Value Per Share | 1.52 X | ||||
| Cash Flow From Operations | (47.27 M) | ||||
| Earnings Per Share | (1.30) X | ||||
| Market Capitalization | 169.61 M | ||||
| Total Asset | 177.41 M | ||||
| Retained Earnings | (355.59 M) | ||||
| Working Capital | 132.15 M | ||||
About Eledon Pharmaceuticals Performance
By examining Eledon Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Eledon Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Eledon Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.6 K | 1.4 K | |
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.23) | (0.25) | |
| Return On Equity | (0.35) | (0.37) |
Things to note about Eledon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Eledon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eledon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eledon Pharmaceuticals had very high historical volatility over the last 90 days | |
| Eledon Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (36.18 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eledon Pharmaceuticals currently holds about 70.46 M in cash with (47.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 57.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Robinson James A. Jr. of 30870 shares of Eledon Pharmaceuticals at 4.04 subject to Rule 16b-3 |
- Analyzing Eledon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eledon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Eledon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eledon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eledon Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eledon Pharmaceuticals' stock. These opinions can provide insight into Eledon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Will Biotechnology sector continue expanding? Could Eledon diversify its offerings? Factors like these will boost the valuation of Eledon Pharmaceuticals. Projected growth potential of Eledon fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Eledon Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Eledon Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Eledon's accounting equity. The concept of intrinsic value - what Eledon Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Eledon Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Eledon Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eledon Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Eledon Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.